Obesity • 25%

Diabetes • 25%

Cardiovascular diseases • 25%

Other • 25%

Oncology • 25%

Neurodegenerative Diseases • 25%

Cardiovascular Diseases • 25%

Infectious Diseases • 25%

Gene therapy • 33%

Immunotherapy • 33%

Neuroprotective agents • 34%

0-5 • 25%

6-10 • 25%

11-20 • 25%

More than 20 • 25%

Increased investment in existing Alzheimer's drugs • 33%

Development of new APOE4-specific treatments • 33%

No significant change in investment • 33%

Cardiovascular diseases • 25%

Neurodegenerative diseases • 25%

Cancer • 25%

Rare genetic disorders • 25%

Cancer • 25%

Alzheimer's Disease • 25%

Cystic Fibrosis • 25%

Sickle Cell Disease • 25%

Neurological disorders • 25%

Muscular disorders • 25%

Metabolic disorders • 25%

No new types • 25%

AI Diagnostics • 33%

Mobile Health Apps • 33%

Wearable Health Devices • 33%

Prostate Cancer • 25%

Breast Cancer • 25%

Lung Cancer • 25%

Pancreatic Cancer • 25%

Significant stock value increase • 33%

Moderate stock value increase • 33%

No significant change • 34%

Medical diagnostics • 33%

Personalized medicine • 33%

Mental health support • 34%